Core Insights - EDAP TMS SA announced interim results from its Phase 3 study on robotic High-Intensity Focused Ultrasound (HIFU) therapy for deep infiltrating endometriosis, involving 60 patients in a randomized, double-blind trial [1][2] Study Results - The Phase 3 study aimed to evaluate acute pelvic pain levels, with patients followed for three months post-treatment [1] - Both HIFU and Sham treatment arms showed significant reductions in pelvic pain scores at three months, but the primary endpoint of reduced acute pelvic pain in the HIFU arm was not met [2][8] - The study's Principal Investigator suggested that the three-month follow-up may have been too short to demonstrate clinically meaningful differences in pain scores [2][10] - MRI results indicated that patients receiving HIFU therapy had greater volume reductions in endometriosis nodules compared to the Sham treatment group [2] Safety Profile - Robotic HIFU therapy maintained an excellent safety profile, consistent with earlier Phase 1 and Phase 2 studies [2][8] - The cumulative safety and efficacy data from all phases of the study suggest that robotic HIFU is a safe, non-invasive treatment option for women suffering from endometriosis [10] Future Outlook - The Phase 3 study will continue as planned, with some patients from the Sham arm opting for HIFU therapy after their pain returned to baseline levels [10] - The CEO of EDAP TMS expressed optimism that longer follow-up periods may reveal a therapeutic benefit favoring robotic HIFU [10] - The company plans to provide further updates on the program later in the year [10] Company Background - EDAP TMS is a leader in the global therapeutic ultrasound market, developing and distributing minimally invasive medical devices for various pathologies using ultrasound technology [4] - The company offers a complete solution for prostate cancer treatment, including the Focal One® and ExactVu™ Micro-Ultrasound devices [4]